ARCHIVES

FDA Approves Inlyta Pill For Renal Cell Carcinoma

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

JCO Retracts Key Duke Genomics Paper; Duke Shuts Down Three Phase II Trials

November 19, 2010

Executive Branch Should Improve Science Pay, NAS Says

July 16, 1993

Other Institutes Fare Well With ’77 Appropriations

August 20, 1976

NCAB Gives Okay To Comp Center Guidelines

December 7, 1979

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

The Raghavan Experiment: With $500 Million to Draw On, An Iconoclast Invents Rational Care for a Gigantic System

January 4, 2013